-Former Cubist CEO-
BOSTON--(BUSINESS WIRE)--Sep. 8, 2015--
to Tweet this News
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is
developing innovative and proprietary treatments for exercise-associated
muscle cramps, nocturnal leg cramps, and spasms associated with severe
neuromuscular conditions, today announced that Robert J. Perez, former
Chief Executive Officer of Cubist Pharmaceuticals, Inc., has joined its
Board of Directors.
Mr. Perez joined Cubist in 2003, as Senior Vice President, Sales and
Marketing and led the launch of Cubicin® (daptomycin for injection). He
served as Executive Vice President and Chief Operating Officer (COO) for
the company from 2007 to 2012 and President and COO from 2012 to 2014.
Prior to joining Cubist, he served as Vice President of Biogen, Inc.’s
CNS Business Unit from 2001 to 2003, where he was responsible for
commercial leadership of an $800 million neurology business unit and
from 1995 to 2001, held positions of increasing responsibility within
the commercial organization. Mr. Perez serves on the Board of Directors
of AMAG Pharmaceuticals (NASDAQ: AMAG) and Cidara Therapeutics (NASDAQ:
CDTX). He is a member of the Board of Trustees of the Dana-Farber Cancer
Institute, Inc., the Board of Advisors of the Citizen School of
Massachusetts and a Board member of the Biomedical Science Careers
Program aimed at increasing the quality of a diverse workforce for the
life sciences. Mr. Perez received a B.S. in business from California
State University, Los Angeles and an M.B.A. from the Anderson Graduate
School of Management at the University of California, Los Angeles.
“With significant growth opportunities for both the consumer and
pharmaceutical arms of the business, I am excited to join the Flex
Pharma Board since the Company is uniquely positioned to help a wide
range of individuals - from athletes to patients - who suffer from
cramps and spasms,” said Rob Perez.
“I’ve long admired Rob as a thought leader in the biotech community and
we are gratified to have his experience successfully transforming a
pre-commercial biotechnology company into a commercial organization as
Flex Pharma grows to become a leading neuromuscular company,” commented
Christoph Westphal, M.D., Ph.D., Chairman and Chief Executive Officer of
Also on the Board of Directors of Flex Pharma are Rod MacKinnon, M.D.,
Nobel Laureate and scientific co-founder; John Sculley, former Apple CEO
and PepsiCo CEO; Peter Barton Hutt, former General Counsel of the U.S.
Food and Drug Administration; Marc Kozin, Senior Advisor to L.E.K.
Consulting; Stuart Randle, former CEO of GI Dynamics; Jeffrey Capello,
former CFO of Ortho-Clinical Diagnostics and Boston Scientific; and Dr.
Westphal, Chairman and Chief Executive Officer of Flex Pharma.
About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that is developing
innovative and proprietary treatments for exercise-associated muscle
cramps, nocturnal leg cramps, and spasms associated with severe
neuromuscular conditions. In three randomized, blinded,
placebo-controlled, cross-over studies, Flex Pharma's proprietary
treatment has shown a statistically significant reduction in the
intensity of muscle cramps in healthy normal volunteers.
Flex Pharma was founded by National Academy of Sciences members Rod
MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized
leaders in the fields of ion channels and neurobiology, along with
Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.
Individuals can follow the Company on twitter (@flexpharma) and the
Company's website (http://ir.flex-pharma.com/)
to see the latest progress of the Company's pre-launch activities for
its consumer product to prevent and treat exercise-associated muscle
View source version on businesswire.com: http://www.businesswire.com/news/home/20150908006053/en/
Source: Flex Pharma, Inc.
Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
Relations & Corporate Communications